OR WAIT null SECS
March 02, 2023
That wave beginning to crash over PhRMA’s gunwales may well emanate from a startup mindset, rather than Big Pharma or government policy pundits.
March 01, 2023
AstraZeneca has entered into a global exclusive license agreement with KYM Biosciences for CMG901, which is being investigated as a gastric cancer treatment.
February 24, 2023
Moderna will leverage Life Edit’s suite of gene editing technologies to advance development of in vivo gene editing therapies.
AbbVie and Capsida have expanded their existing collaboration to advance three new gene therapy programs.
The goal of this collaboration is to develop an approach to personalized radiotherapy and drug discovery that is based in genomics and artificial intelligence.
February 21, 2023
LIfT and Minaris will work together to develop a manufacturing process for LIfT’s allogeneic neutrophil progenitor cell therapy.
February 15, 2023
Takeda’s acquisition of Nimbus Lakshmi will grant them rights to NDI-034858, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases.
In the coming year, pharmaceutical innovation will be fueled by key trends throughout the quality sector.
The COVID-19 pandemic helped to showcase RNA molecules and their therapeutic potential. There were also lessons learned in terms of drug delivery, manufacturing, logistics, and storage.
February 09, 2023
Biden outlined a host of priorities for improving health care and building the economy during State of the Union address.